RxDoctor Payments Data

Brittany Heckel, MD

Neurology · Philadelphia, PANPI 1497280226

Payments from drug & device makers

$5,628in general payments, 2019–2025

Across 162 payments — averaging $34.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Lilly USA, LLC$904
  • Amgen$353
  • Teva Pharmaceuticals USA, Inc.$282
  • Biohaven Pharmaceutical Holding Company Ltd.$186
  • Pfizer$159
  • plus $379 from 8 others

What the payments were for

  • Consulting fees$1,30023%
  • Food & beverage$4,32877%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,628 in reported general payments places this provider in the 65th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$19,930
Medicare patients
103
Services billed
202

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe42$36,015
Emgality PenGalcanezumab-Gnlm39$28,501
Nurtec OdtRimegepant Sulfate15$26,891
Emgality SyringeGalcanezumab-Gnlm15$25,698
UbrelvyUbrogepant12$11,832
Mexiletine Hcl18$1,680
Amitriptyline Hcl25$678
Topiramate77$676
Propranolol Hcl ErPropranolol Hcl24$529
RizatriptanRizatriptan Benzoate29$411
Duloxetine Hcl42$330
Nortriptyline Hcl12$319
Lacosamide12$238
Prochlorperazine Maleate41$231
Sumatriptan Succinate14$174

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$159$26,89115 claims
AbbVieUbrelvy$3,367$11,83212 claims
Upsher-smith Laboratories LLCTopiramate$149$67677 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →